Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 11/2008

01-11-2008 | Original Article

Measurement of the internal dose to families of outpatients treated with 131I for hyperthyroidism

Authors: S. F. Barrington, P. Anderson, A. G. Kettle, R. Gadd, W. H. Thomson, S. Batchelor, P. J. Mountford, L. K. Harding, M. J. O’Doherty

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 11/2008

Login to get access

Abstract

Objective

The aim of this study was to measure the internal dose received by family members from ingestion of radioactive contamination after outpatient therapy.

Materials and methods

Advice was given to minimise transfer of radioiodine. Home visits were made approximately 2, 7 and 21 days after treatment to measure radioactivity in the thyroids of family members. A decay correction was applied to radioactivity detected assuming ingestion had occurred at the earlier contact time, either the day of treatment or the previous home visit. An effective half-life of 6 or 7 days was used depending on age. Thyroid activity was summed if activity was found at more than one visit in excess of the amount attributable to radioactive decay. Effective dose (ED) was calculated using ICRP72.

Results and discussion

Fifty-three adults and 92 children, median age 12 (range 4–17) years participated. Median administered activity was 576 (range 329–690) MBq 131I. Thyroid activity ranged from 0 to 5.4 kBq in the adults with activity detected in 17. Maximum adult ED was 0.4 mSv. Thyroid activity ranged from 0 to 11.8 kBq in the children with activity detected in 26. The two highest values of 5.0 and 11.8 kBq occurred in children aged 5 and 14 years from different families. Eighty-five children had no activity or <1 kBq detected. ED was <0.2 mSv in 86 out of 92 children (93%). Previous published data showed 93% of children received an ED ≤0.8 mSv from external irradiation.

Conclusion

With advice, families of outpatients receiving radioiodine should be able to comply with statutory dose limits and constraints.
Literature
1.
go back to reference Council Directive 96/29/Euratom of 13th May 1996. Laying down basic safety standards for the protection of the health of workers and the general public against the dangers arising from ionising radiation. OJ 1996; No L 159: p.1–114. Council Directive 96/29/Euratom of 13th May 1996. Laying down basic safety standards for the protection of the health of workers and the general public against the dangers arising from ionising radiation. OJ 1996; No L 159: p.1–114.
2.
go back to reference Ionising radiation regulations. Work with ionising radiation. Approved code of practice and practical guidance on the Ionising Radiation Regulations. London: HMSO 1999;SI 3232. Ionising radiation regulations. Work with ionising radiation. Approved code of practice and practical guidance on the Ionising Radiation Regulations. London: HMSO 1999;SI 3232.
3.
go back to reference Council Directive 97/43/Euratom of June 1997. On health protection of individuals against the dangers of ionising radiation in relation to medical exposure. OJ 1997;No L180: p.22–27. Council Directive 97/43/Euratom of June 1997. On health protection of individuals against the dangers of ionising radiation in relation to medical exposure. OJ 1997;No L180: p.22–27.
4.
go back to reference Medical and Dental Guidance Notes. A good practice guide on all aspects of ionising radiation protection in the clinical environment. York: Institute of Physics and Engineering in Medicine; 2002. Medical and Dental Guidance Notes. A good practice guide on all aspects of ionising radiation protection in the clinical environment. York: Institute of Physics and Engineering in Medicine; 2002.
6.
go back to reference Singelton M, Griffiths C, Morrison G, Soanes T. Dose constraints for comforters and carers Research report 155. 2003. Norwich: HMSO; 2003. Singelton M, Griffiths C, Morrison G, Soanes T. Dose constraints for comforters and carers Research report 155. 2003. Norwich: HMSO; 2003.
7.
go back to reference Barrington SF, O’Doherty MJ, Kettle AG, Thomson WH, Mountford PJ, Burrell DN, et al. Radiation exposure of the families of outpatients treated with radioiodine (131I) for hyperthyroidism. Eur J Nucl Med Mol Imaging 1999;26:686–92.CrossRef Barrington SF, O’Doherty MJ, Kettle AG, Thomson WH, Mountford PJ, Burrell DN, et al. Radiation exposure of the families of outpatients treated with radioiodine (131I) for hyperthyroidism. Eur J Nucl Med Mol Imaging 1999;26:686–92.CrossRef
8.
go back to reference Monsieurs M, Thierens H, Dierckx RA, Casier K, De Baere E, De Ridder L, et al. Real-life radiation burden to relatives of patients treated with iodine-131: a study in eight centres in Flanders (Belgium). Eur J Nucl Med Mol Imaging 1998;25:1368–76.CrossRef Monsieurs M, Thierens H, Dierckx RA, Casier K, De Baere E, De Ridder L, et al. Real-life radiation burden to relatives of patients treated with iodine-131: a study in eight centres in Flanders (Belgium). Eur J Nucl Med Mol Imaging 1998;25:1368–76.CrossRef
9.
go back to reference Jacobson AP, Plato PA, Toeroek D. Contamination of the home environment by patients treated with Iodine-131: initial results. Am J Public Health 1978;68:225–30.PubMed Jacobson AP, Plato PA, Toeroek D. Contamination of the home environment by patients treated with Iodine-131: initial results. Am J Public Health 1978;68:225–30.PubMed
10.
go back to reference Buchan RCT, Brindle JM. Radioiodine therapy to out-patients—the contamination hazard. Br J Radiol 1970;43:479–82.PubMedCrossRef Buchan RCT, Brindle JM. Radioiodine therapy to out-patients—the contamination hazard. Br J Radiol 1970;43:479–82.PubMedCrossRef
11.
go back to reference Buchan RCT, Brindle JM. Radioiodine therapy to out-patients—the radiation hazard. Br J Radiol 1971;44:973–5.PubMed Buchan RCT, Brindle JM. Radioiodine therapy to out-patients—the radiation hazard. Br J Radiol 1971;44:973–5.PubMed
12.
go back to reference Reiners C, Laβmann M. Radioiodine (131I) treatment of hyperthyroidism: radiation protection and quality assurance. Eur J Nucl Med 1999;26:683–68.PubMedCrossRef Reiners C, Laβmann M. Radioiodine (131I) treatment of hyperthyroidism: radiation protection and quality assurance. Eur J Nucl Med 1999;26:683–68.PubMedCrossRef
13.
go back to reference Ibis E, Wilson CR, Collier BD, Akansel G, Isitman AT, Yoss RG. Iodine-131 contamination from thyroid cancer patients. J Nucl Med 1992;33:2110–5.PubMed Ibis E, Wilson CR, Collier BD, Akansel G, Isitman AT, Yoss RG. Iodine-131 contamination from thyroid cancer patients. J Nucl Med 1992;33:2110–5.PubMed
14.
go back to reference O’Doherty MJ, Kettle AG, Eustance CNP, Mountford PJ, Coakley AJ. Radiation dose rates from adult patients receiving 131I therapy for thyrotoxicosis. Nuclear Med Commun 1993;14(3):160–8.CrossRef O’Doherty MJ, Kettle AG, Eustance CNP, Mountford PJ, Coakley AJ. Radiation dose rates from adult patients receiving 131I therapy for thyrotoxicosis. Nuclear Med Commun 1993;14(3):160–8.CrossRef
15.
go back to reference Johansson L, Leide-Svegborn S, Mattsson S, Nosslin B. Biokinetics of iodide in man: refinement of current ICRP dosimetry models. Cancer Biother Radiopharm 2003;18(3):445–50.PubMedCrossRef Johansson L, Leide-Svegborn S, Mattsson S, Nosslin B. Biokinetics of iodide in man: refinement of current ICRP dosimetry models. Cancer Biother Radiopharm 2003;18(3):445–50.PubMedCrossRef
16.
go back to reference Sumerling, TJ, Darby, SC. Statistical aspects of the interpretation of counting experiments designated to detect low levels of radioactivity. R113. Chilton: NRPB; 1981. Sumerling, TJ, Darby, SC. Statistical aspects of the interpretation of counting experiments designated to detect low levels of radioactivity. R113. Chilton: NRPB; 1981.
17.
go back to reference International Commission on Radiological Protection. Age-dependant Doses to members of the public from intake of radionuclides: Part 1. ICRP publication 56. Oxford: Pergamon Press; 1989. International Commission on Radiological Protection. Age-dependant Doses to members of the public from intake of radionuclides: Part 1. ICRP publication 56. Oxford: Pergamon Press; 1989.
18.
go back to reference International Commission on Radiological Protection. Age-dependant doses to members of the public from intake of radionuclides: Part 5 Compilation of ingestion and inhalation dose coefficients. ICRP Publication 72. Oxford: Pergamon Press; 1996. International Commission on Radiological Protection. Age-dependant doses to members of the public from intake of radionuclides: Part 5 Compilation of ingestion and inhalation dose coefficients. ICRP Publication 72. Oxford: Pergamon Press; 1996.
19.
go back to reference International Commission on Radiological Protection. 1990 Recommendations of the ICRP. ICRP Publication 60. Oxford: Pergamon Press; 1994. International Commission on Radiological Protection. 1990 Recommendations of the ICRP. ICRP Publication 60. Oxford: Pergamon Press; 1994.
20.
go back to reference Grigsby PW, Siegel BA, Baker S, Eichling JO. Radiation exposure from outpatient radioactive iodine [131I] therapy for thyroid carcinoma. JAMA 2000;283:2272–4.PubMedCrossRef Grigsby PW, Siegel BA, Baker S, Eichling JO. Radiation exposure from outpatient radioactive iodine [131I] therapy for thyroid carcinoma. JAMA 2000;283:2272–4.PubMedCrossRef
21.
go back to reference Mathieu I, Caussin J, Smeesters P, Wambersie A, Beckers C. Recommended restrictions after 131I therapy: measured doses in family members. Health Phys 1999;76:129–36.PubMed Mathieu I, Caussin J, Smeesters P, Wambersie A, Beckers C. Recommended restrictions after 131I therapy: measured doses in family members. Health Phys 1999;76:129–36.PubMed
22.
go back to reference Jentzen W, Gorges R, Freudenberg L, Eising EG, Muller SP, Bockisch A. Influence of various geometric factors on the iodine-131 uptake measurement for solitary thyroid nodules. Nucl Med Comm 2008;29:398–404.CrossRef Jentzen W, Gorges R, Freudenberg L, Eising EG, Muller SP, Bockisch A. Influence of various geometric factors on the iodine-131 uptake measurement for solitary thyroid nodules. Nucl Med Comm 2008;29:398–404.CrossRef
23.
go back to reference Rahu M. Health effects of the Chernobyl accident: fears, rumours and the truth. Eur J Cancer 2003;39:295–9.PubMedCrossRef Rahu M. Health effects of the Chernobyl accident: fears, rumours and the truth. Eur J Cancer 2003;39:295–9.PubMedCrossRef
24.
go back to reference Cardis E, Kesminiene A, Ivanov V, Malakhova I, Shibata Y, Khrouch V, et al. Risk of thyroid cancer after exposure to 131I in childhood. J Natl Cancer Inst 2005;97(10):724–32.PubMedCrossRef Cardis E, Kesminiene A, Ivanov V, Malakhova I, Shibata Y, Khrouch V, et al. Risk of thyroid cancer after exposure to 131I in childhood. J Natl Cancer Inst 2005;97(10):724–32.PubMedCrossRef
26.
go back to reference Gavrilin Y, Khrouch V, Shinkarev S, Drozdovitch V, Minenko V, Shemiakina E, et al. Individual thyroid dose estimation for a case-control study of Chernobyl-related thyroid cancer among children of Belarus—part I: 131I, short-lived radioiodines (132I, 133I, 135I), and short-lived radiotelluriums (131MTe and 132Te). Health Physics 2004;86(6):565–85.PubMedCrossRef Gavrilin Y, Khrouch V, Shinkarev S, Drozdovitch V, Minenko V, Shemiakina E, et al. Individual thyroid dose estimation for a case-control study of Chernobyl-related thyroid cancer among children of Belarus—part I: 131I, short-lived radioiodines (132I, 133I, 135I), and short-lived radiotelluriums (131MTe and 132Te). Health Physics 2004;86(6):565–85.PubMedCrossRef
27.
go back to reference Davis S, Kopecky KJ, Hamilton TE, Onstad L. Thyroid neoplasia, autoimmune thyroiditis and hypothyroidism in persons exposed to Iodine 131 from the Hanford Nuclear Site. JAMA 2004;292:2600–13.PubMedCrossRef Davis S, Kopecky KJ, Hamilton TE, Onstad L. Thyroid neoplasia, autoimmune thyroiditis and hypothyroidism in persons exposed to Iodine 131 from the Hanford Nuclear Site. JAMA 2004;292:2600–13.PubMedCrossRef
28.
go back to reference Rivkees SA, Dinauer C. An optimal treatment for Pediatric Graves’ Disease is radioiodine. J Clin Endocrinol Metab 2007;92:797–800.PubMedCrossRef Rivkees SA, Dinauer C. An optimal treatment for Pediatric Graves’ Disease is radioiodine. J Clin Endocrinol Metab 2007;92:797–800.PubMedCrossRef
29.
go back to reference Lucignani G. Long-term risks in hyperthyroid patients treated with radioiodine: is there anything new. Eur J Nucl Med Mol Imaging 2007;34(9):1504–9.PubMedCrossRef Lucignani G. Long-term risks in hyperthyroid patients treated with radioiodine: is there anything new. Eur J Nucl Med Mol Imaging 2007;34(9):1504–9.PubMedCrossRef
Metadata
Title
Measurement of the internal dose to families of outpatients treated with 131I for hyperthyroidism
Authors
S. F. Barrington
P. Anderson
A. G. Kettle
R. Gadd
W. H. Thomson
S. Batchelor
P. J. Mountford
L. K. Harding
M. J. O’Doherty
Publication date
01-11-2008
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 11/2008
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-008-0892-0

Other articles of this Issue 11/2008

European Journal of Nuclear Medicine and Molecular Imaging 11/2008 Go to the issue